The Fund generally will invest at least 90% of its total assets in thesecurities that comprise the Underlying Index.Strictly in accordance with its guidelines and mandated procedures,Nasdaq, Inc. (Nasdaq or the Index Provider) compiles the UnderlyingIndex, which is a modified market capitalization weighted index that isdesigned to measure the performance of securities listed on the NasdaqStock Market that are classified as either biotechnology or pharmaceuticalcompanies. Eligible securities must be classified under the biotechnologysubsector or pharmaceuticals subsector of the Industry ClassificationBenchmark (ICB), have a minimum market capitalization of $200 millionat the time of the Underlying Indexs annual rebalancing, and have aminimum average daily trading volume of 100,000 shares.